CiNTL Pharma B.V., Announce Strategic Partnership with SmartCatch
July 8, 2025

CiNTL Pharma B.V. and SmartCatch Announce Strategic Partnership to Advance Agentic AI in Clinical Research and Oncology Diagnostics

 

Leiden, The Netherlands, July 8, 2025 - CiNTL Pharma B.V., a Netherlands-based, data-driven contract research organization (CRO), and SmartCatch, a French MedTech innovator in circulating tumor cell (CTC) technologies, have announced the signing of a strategic Memorandum of Understanding (MoU) to collaborate on advancing precision oncology and AI-driven clinical research solutions globally.

This partnership unites CiNTL Pharma’s vision for agentic software in clinical trial design and execution with SmartCatch’s pioneering X-Tracker™ technology, a fully automated, label-free platform that isolates viable CTCs from whole blood and other biofluids, enabling unprecedented insight into tumor biology and treatment response.

 

Driving Innovation in Oncology Diagnostics and Agentic Clinical Research

Through this collaboration, CiNTL Pharma and SmartCatch aim to co-develop and pilot AI-powered, patient-centric research solutions, with a focus on making oncology trials more adaptive, intelligent, and accessible. The partnership will explore the integration of SmartCatch’s next-generation diagnostic capabilities into CiNTL Pharma’s agentic AI platform for clinical trial automation and regulatory compliance.

 

“We are excited to join forces with SmartCatch to accelerate the future of personalized oncology and agentic CRO models,” said Yolanda Cabrera-Sybesma, CEO of CiNTL Pharma B.V. “By combining our software innovation with their breakthrough CTC technology, we’re setting a new standard for how clinical research is conducted, more intelligent, more responsive, and more inclusive.”

 

“Our partnership with CiNTL Pharma is a powerful step forward in our mission to bring CTCs into everyday clinical practice,” said Dr. Aline Cerf, Co-Founder and CEO of SmartCatch. “Together, we’re not just supporting new therapies development and oncology trials — we’re transforming them, with real-time biological insights driving smarter, faster, and more scalable decisions.”

 

A Shared Vision for Global Health Impact

This alliance marks a major step in creating an ecosystem of technologies that connect diagnostic insight with agentic decision-making in regulated clinical settings. Both organizations are committed to ethical innovation, scientific excellence, and building scalable solutions that improve patient outcomes and accelerate therapeutic development worldwide.

 

About CiNTL Pharma B.V.

CiNTL Pharma is a data-driven, female-founded CRO based in the Netherlands. It is pioneering an agentic AI platform to radically transform clinical research design, regulatory workflows, and execution. With a focus on automation, and equity, CiNTL empowers pharma and biotech companies to run faster, smarter, and more compliant clinical trials.

Website: www.cintlpharma.com

 

About SmartCatch

SmartCatch is a microtech-driven, female co-founded medtech based in France. SmartCatch specializes in real-time, physical isolation of circulating tumor cells (CTCs) from whole blood and other biofluids using its proprietary X-Tracker™ technology. With a mission to revolutionize cancer diagnostics and research, SmartCatch enables live-cell, label-free CTC detection to drive personalized therapy decisions and breakthrough cancer research.

Website: www.smartcatch.fr

 

For media inquiries, partnerships, or collaborations, please contact CiNTL Pharma Business Developement at BD@cintlpharma.com.